Table 1 Input Data: Epidemiology, Vaccine Characteristics and Utilities
Base case | Deterministic sensitivity analysis | |||
|---|---|---|---|---|
HZ | PHN | HZ | PHN | |
Epidemiology | ||||
Annual HZ Incidence (per 1,000 people)/PHN Proportion per HZ case | Gauthier 2008 [11] | Edmunds 2001 [12] | ||
Age 50 - 54 | 3.34 | 10.30% | 4.61 | - |
Age 55 - 59 | 4.08 | 13.70% | 5.21 | - |
Age 60 - 64 | 4.90 | 15.70% | 5.92 | - |
Age 65 - 69 | 5.96 | 18.70% | 6.70 | - |
Age 70 - 74 | 6.34 | 22.50% | 7.53 | - |
Age 75 - 79 | 7.09 | 26.60% | 8.42 | - |
Age 80 - 84 | 7.29 | 28.90% | 9.37 | - |
Age 85+ | 6.22 | 25.90% | 11.58 | - |
Mean Duration (in months) | SPS Trial 2005 [6] | Gauthier 2008 [11] | ||
Age ≤ 69 | 1.0 | 10.3 | - | 10.9 |
Age ≥ 70 | 1.0 | 12.9 | - | 11.0 |
Annual HZ Mortality Rate | Assumption | Edmunds 2001 [12] | ||
Age 50 - 54 | 0% | - | 0.0009% | - |
Age 55 - 59 | 0% | - | 0.0009% | - |
Age 60 - 64 | 0% | - | 0.0027% | - |
Age 65 - 69 | 0% | - | 0.0027% | - |
Age 70 - 74 | 0% | - | 0.0035% | - |
Age 75 - 79 | 0% | - | 0.0092% | - |
Age 80 - 84 | 0% | - | 0.0487% | - |
Age 85+ | 0% | - | 0.2018% | - |
Gender split | Gauthier 2008 [11] | |||
% female | 61% | 65% | ||
Pain severity split at diagnosis | SPS Trial 2005 [6] | Gauthier 2008 [11] | ||
Age ≤ 69 | ||||
No pain | 27% | - | 65% | - |
Mild pain | 41% | 42% | 24% | 47% |
Moderate pain | 18% | 9% | 4% | 42% |
Severe pain | 14% | 49% | 8% | 11% |
Age ≥ 70 | ||||
No pain | 26% | - | 45% | - |
Mild pain | 32% | 17% | 41% | 34% |
Moderate pain | 23% | 16% | 5% | 54% |
Severe pain | 19% | 67% | 9% | 12% |
Recurrent annual HZ Incidence | ||||
Age 50 - 54 | 0.10% | - | ||
Age 55 - 59 | 0.12% | - | ||
Age 60 - 64 | 0.15% | - | ||
Age 65 - 69 | 0.18% | - | ||
Age 70 - 74 | 0.23% | - | ||
Age 75 - 79 | 0.31% | - | ||
Age 80 - 84 | 0.42% | - | ||
Age 85 - 89 | 0.58% | - | ||
Age 90 - 94 | 0.83% | - | ||
Age 95 - 99 | 1.15% | - | ||
Age 100+ | 1.40% | - | ||
Quality of Life | ||||
Utility Decrements | Oster 2005 [13] | |||
No pain | 0.00 | - | 0.14/0.00 | - |
Mild pain | 0.31 | 0.31 | 0.23/0.27 | 0.23/0.27 |
Moderate pain | 0.42 | 0.42 | 0.32/0.40 | 0.32/0.40 |
Severe pain | 0.75 | 0.75 | 0.45/0.53 | 0.45/0.53 |
Vaccine characteristics | SPS Trial 2005 [6] | |||
Efficacy: total % reduction in cases (PHN direct effect) | ||||
Age ≤ 69 | 63.9% | 66.7% (4.8%) | ||
Age ≥ 70 | 37.6% | 66.8% (30.0%*) | ||
Efficacy: number of months reduction of PHN pain | ||||
Age ≤ 69 | - | -2.2 | ||
Age ≥ 70 | - | -3.3 | ||